文献速递眼底病与葡萄膜炎

难治性新生血管性年龄相关性黄斑变性持续双周阿柏西普治疗:前瞻性TRISTAR研究

SUSTAINED BIWEEKLY AFLIBERCEPT FOR REFRACTORY NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Prospective TRISTAR Study.
PubMed 文献 · Retina · 2023-01-01

前瞻性单臂干预研究纳入22只难治性新生血管性年龄相关性黄斑变性(NVAMD)眼,接受每2周一次阿柏西普2 mg玻璃体内注射6次至第12周,暂停4周至第16周;第16周仍有残余视网膜下液(SRF)者随机1:1接受额外4次双周注射或4周间隔注射至第24周,之后全部改为4周间隔至第52周。双周给药期间最佳矫正视力(BCVA)和中心亚视野厚度(CST)显著改善,但恢复每月给药后改善丧失。

要点

  • 难治性NVAMD眼双周阿柏西普注射至第14周BCVA平均提高2.52字母(P < 0.001),CST平均降低31.9 µ m(P < 0.001)。
  • 第14周22只眼中8只SRF完全消退,但第16周暂停后仅8只中2只仍无SRF,CST较第14周平均增加26.7 µ m。
  • 至第52周BCVA和CST改善均丧失,提示双周给药需持续才能维持获益。

核心结论

  • 在难治性NVAMD相关SRF患者中,持续双周阿柏西普注射在双周给药期间带来显著功能和解剖改善,但恢复每月给药后这些获益丧失。
  • 作者认为,若持续双周给药,减少难治性SRF的努力可能较标准治疗提供额外获益。

研究设计与样本

  • 前瞻性、单臂、干预性研究。
  • 纳入22只难治性NVAMD眼,既往12个月平均接受11.8次注射后仍有持续性SRF。
  • 所有眼接受6次双周阿柏西普2 mg玻璃体内注射至第12周,暂停4周至第16周;第16周有残余SRF的眼随机1:1接受额外4次双周注射或4周间隔注射至第24周,之后全部改为4周间隔至第52周。

主要发现

  • BCVA从基线至第14周显著改善2.52字母(P < 0.001)。
  • 第14周CST显著改善-31.9 µ m(P < 0.001),22只眼中8只SRF完全消退。
  • 第16周仅8只中2只仍无SRF,CST较第14周平均增加26.7 µ m。
  • 至第52周BCVA和CST改善均丧失。
  • 1例患者在第12周发生眼内炎,无其他药物或操作相关不良事件。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the safety and efficacy of biweekly (every 2 weeks) intravitreal aflibercept injections (IAI) 2 mg in eyes with refractory neovascular age-related macular degeneration (NVAMD). METHODS: A prospective, single-arm, interventional study was conducted. Eyes with refractory NVAMD received six biweekly IAIs through week 12, followed by a 4-week treatment pause until week 16. Eyes with residual subretinal fluid (SRF) at week 16 were randomized 1:1 to either four additional biweekly IAIs or to 4-week (q4W) IAI dosing through week 24. All eyes were subsequently treated q4W through week 52. RESULTS: Enrolled eyes (n = 22) had persistent SRF despite a mean of 11.8 injections over the prior 12 months. One patient developed endophthalmitis at week 12. There were no additional drug/procedure-related adverse events. Best-corrected visual acuity (BCVA) improved significantly from baseline to week 14 (2.52 letters, P < 0.001). The mean central subfield thickness (CST) was also significantly improved at week 14 (-31.9 µ m, P < 0.001) with eight of 22 eyes achieving complete SRF resolution. Only two of eight eyes remained free of SRF at week 16, with a corresponding increase in mean CST of 26.7 µ m compared with week 14. By week 52, improvements in BCVA and CST were lost. CONCLUSION: In patients with refractory NVAMD-related SRF, sustained biweekly IAIs resulted in significant functional and anatomical improvements during biweekly dosing. These gains, however, were lost on return to monthly dosing. These findings suggest that efforts to reduce refractory SRF in NVAMD with biweekly dosing may provide added benefit compared with standard of care treatment if biweekly dosing is sustained.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Schneider EW, Thomas MK, Recchia FM, et al. SUSTAINED BIWEEKLY AFLIBERCEPT FOR REFRACTORY NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Prospective TRISTAR Study. Retina. 2023. PMID: 36728874. doi:10.1097/IAE.0000000000003729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。